Green tea catechins and their metabolites in human skin before and after exposure to ultraviolet radiation

Kayleigh A. Clarke, Tristan P. Dew, Rachel E.B. Watson, Mark D. Farrar, Joanne E. Osman, Anna Nicolaou, Lesley E. Rhodes, Gary Williamson

Abstract

Dietary flavonoids may protect against sunburn inflammation in skin. Preliminary reports using less complete analysis suggest that certain catechins and their metabolites are found in skin biopsies and blister fluid after consumption of green tea; however, it is not known if they are affected by solar-simulated ultraviolet radiation (UVR) or whether conjugated forms, with consequently altered bioactivity, are present. The present study tested the hypothesis that UVR affects the catechin levels in the skin of healthy volunteers after consumption of green tea and how catechins in the plasma are related to their presence in skin tissue samples. In an open oral intervention study, 11 subjects consumed green tea and vitamin C supplements daily for 3 months. Presupplementation and postsupplementation plasma samples, suction blister fluid and skin biopsies were collected; the latter two samples were collected both before and after UVR. A sensitive high-performance liquid chromatography/mass spectrometric assay was used to measure the intact catechin metabolites, conjugates and free forms. Seven green tea catechins and their corresponding metabolites were identified postsupplementation in skin biopsies, 20 in blister fluid and 26 in plasma, with 15 sensitive high-performance liquid chromatography/mass spectrometric assay was used to measure the intact catechin metabolites, conjugates and free forms. Seven green tea catechins and their corresponding metabolites were identified postsupplementation in skin biopsies, 20 in blister fluid and 26 in plasma, with 15

1. Introduction

Daily consumption of green tea is associated with positive effects on human health [1–5]. Epidemiological studies have correlated green

Abbreviations: AA, ascorbic acid; BMI, body mass index; C, catechin; $C_{\text{max}}$, peak plasma concentration; EC, epicatechin; EG, ethyl gallate; EGC, epigallocatechin; EGCg, epigallocatechin gallate; ECg, epicatechin gallate; IS, internal standard; LC-MS/MS, liquid chromatography tandem mass spectrometry; LOQ, limit of quantification; Me, methyl; MED, minimal erythema dose; SE, standard error; $t_{\text{max}}$, time to reach maximum plasma concentration; UVR, ultraviolet radiation

* The present work was supported by the Biotechnology and Biological Sciences Research Council, Diet and Health Research Industry Club, United Kingdom (grants BB/G005559/1 and BB/GS0125/1).

** Conflicts of interest: none.

Black and white printing is required.

Corresponding author. School of Food Science and Nutrition, University of Leeds, Woodhouse Lane, Leeds, Yorkshire LS2 9JT, United Kingdom. Tel.: +44-113-3438380.

E-mail address: g.williamson@leeds.ac.uk (G. Williamson).

Keywords: Green tea catechin conjugates; Polyphenols; Bioavailability; Ultraviolet radiation; Skin

Received 30 March 2015; received in revised form 3 September 2015; accepted 3 September 2015

http://dx.doi.org/10.1016/j.jnutbio.2015.09.001

0955-2863/© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Green tea contains catechins, a subgroup of the flavonoids, including catechin (C), epicatechin (EC), epigallocatechin (EGC), epicatechin gallate (ECG) and epigallocatechin gallate (EGCG). Previous bioavailability studies have identified that, following consumption, green tea catechins undergo phase II metabolism, and pharmacokinetic studies have shown the presence of the conjugated forms in plasma, with EGCG and ECG partially present as unconjugated forms [24,25]. Recent bioavailability studies have focused mainly on the conjugated forms of catechin metabolites in urine and plasma samples [26–28]. The presence of green tea catechins in various tissues has also been identified in vivo [29,30], including our previous pilot study [31]; however, the conjugated forms have not been assessed previously. This is important since the metabolites and conjugates of catechins have very different biological activities and transport properties compared to the parent compounds.

In our previous pilot study [31], we made a preliminary identification of 8 green tea catechins (presence or absence following enzyme deconjugation assays) in skin biopsy samples, after the daily consumption of green tea catechin supplements and vitamin C (at the equivalent of 2 cups of green tea) for 3 months. The present study utilized an improved method [32], which is applicable for monitoring both the free and conjugated forms of green tea catechins in biological samples, particularly for those containing endogenous β-glucuronidase and sulfatase activities, following daily green tea and vitamin C supplement consumption (at the equivalent of 5 cups of green tea). We used this method to evaluate their oral bioavailability in skin by obtaining and assessing skin biopsies and blister fluid (pre-UVR and post-UVR), plasma and urine to understand whether the presence of catechins in tissues can be related to plasma.

2. Materials and methods

2.1. Study design

A total of 12 subjects were recruited between September 2011 and January 2012 for the 3-month open oral intervention study conducted in the Photobiology Unit, Centre for Dermatology Research, Salford Royal NHS Foundation Hospital (Manchester, United Kingdom). Inclusion criteria were as follows: healthy, aged 18–65 years, sun-reactive skin type I/II and body mass index (BMI) <35 kg/m². Exclusion criteria were as follows: history of skin cancer, photosensitivity disorder or atopy, sunbathing or use of sunbeds in the past 3 months, taking photoactive medication or nutritional supplements and drinking >2 cups of tea per day.

Subjects consumed supplements daily that were the equivalent of 5 cups of green tea. Green tea supplements were gelatine capsules each containing 450 mg green tea (180 mg green tea catechins) and a further set of capsules each containing 25 mg vitamin C. Subjects were administered 3 green tea and 2 vitamin C capsules twice daily (to consume with breakfast and the evening meal; total 1080 mg green tea catechins and 100 mg vitamin C daily) for 12 weeks. Vitamin C was added to stabilize the green tea extract in the gut lumen [33] and has no impact on UVR erythema [34]. During the course of the study, four sample types were collected; plasma, skin blister fluid, skin biopsies and urine (Table 1). Urine was collected over 24 h at four points during the intervention: baseline (day 7–9, presupplementation), day 0 (postsupplementation), week 6 and week 12. Plasma was collected for the pharmacokinetic analysis on the first day of supplementation (day 0) and again at 3 h postconsumption during week 12. All samples were stored at –80°C prior to analysis.

2.2. Ethics

Ethics approval was received from the North Manchester Research Ethics Committee (reference 08/H1006/79; clinicaltrials.gov identifier: NCT01032031). All subjects gave written informed consent and the study conformed to the Declaration of Helsinki principles.

2.3. UVR exposure and skin sampling procedures

Solar-simulated radiation (Newport Spectra Physics Ltd, Didcot, United Kingdom), mimicking the UVR emission of sunlight (290–400 nm; 95% UVB and 5% UVA), was used for all UVR exposures. The light source was located 10 cm away from the skin and a radiometer was used to calibrate the source and confirm consistency of application. To determine the sunburn threshold, skin was irradiated with a geometric series of 10 doses of UVR. After 24 h, the lowest dose that produced a visually discernible erythema was defined as the minimal erythema dose (MED). This determined the UVR dose that was subsequently used in the study; a dose that was 3 times the individual’s MED was applied to buttock skin 24 h prior to skin tissue and blister fluid sampling.

Skin was sampled at presupplementation baseline and 12 weeks postsupplementation, with UVR exposures performed on one buttock and the other buttock providing control unexposed samples. Suction blister and punch biopsy procedures were performed as described previously [18]. Skin biopsies (5 mm punch) were snap frozen in liquid nitrogen. Blister fluid was removed with a needle and combined with 25 μl NaH2PO4 (0.4 mol/L with 200 ml l-Lascobic acid (AA) and 1 g/L EDTA, pH 3.6) then snap frozen in liquid nitrogen. All samples were stored at –80°C prior to analysis.

2.4. Pharmacokinetics

Pharmacokinetic analysis of green tea catechin uptake and metabolism was performed as follows (Table 1). Subjects were instructed to fast from midnight. The following morning, an 18-G cannula was inserted into the right antecubital fossa. A baseline blood sample was taken and then subjects consumed a standard breakfast consisting of flavonoid-free cereal (cornflakes) with semi-skimmed milk, one slice of white toast with butter and a glass of water. A single oral dose of green tea catechins (540 mg total green tea catechins) with 50 mg vitamin C was administered 5 min after consumption of breakfast. Further blood samples were taken at 0.5, 1, 1.5, 2, 3, 4 and 6 h postsupplement consumption with subjects consuming a standard lunch of a cheese and chicken sandwich on white bread and a slice of flavonoid-free cake following the 4-h sample. Plasma was separated by centrifugation, stored at –80°C and analyzed as described below.

2.5. Materials

EC, EGC, ECG, EGCG, C and taxifolin were purchased from Extrasynthese (Genay, France). Ethyl gallate (EG) and 3-methyl gallic acid were obtained from A-pin Chemicals Ltd (Oxfordshire, United Kingdom), hippuric acid, benzoic acid and 3-hydroxybenzoic acid were purchased from Fluka (Dorset, United Kingdom); AA was from Sigma Aldrich (Dorset, United Kingdom) and syringic acid and gallic acid were purchased from Alfa Aesar (Lancashire, United Kingdom). All standards were high-performance liquid chromatography grade (>99%). EC-O-sulfate and EGC-O-glucuronide were synthesized using the method by Wong et al. [35]. A Millipore Q water purifying system (Millipore, Hertfordshire, United Kingdom) provided ultrapure water (≥18.2 M Ω cm at 25°C) for liquid chromatography tandem mass spectrometry (LC-MS/MS) analysis. Standard curves were generated for aglycones (free forms) by spiking standards into blank, presupplementation plasma and blister samples (R²≥0.97). Recoveries were calculated by spiking known amounts of standards into blank, presupplementation plasma, blister and biopsy samples (postcopolymerization) and relating the peak area from the spiked sample to the peak area from the direct analysis of an equivalent volume by LC-MS/MS.

2.6. Sample analysis

2.6.1. Urine analysis for compliance

Urine was extracted into HCl-washed flasks containing AA (~1 g/L) and stored at –80°C prior to analysis. Compliance to the study was tested through monitoring the presence of EC-O-sulfate and EGC-O-glucuronide in the urine during the trial at the four time points and by counting residual supplements (Table 1). The urine samples were analyzed by LC-MS/MS according to our previous method [32].

2.6.2. Plasma analysis

Plasma samples were removed from –80°C storage and thawed on ice. The whole procedure was performed on ice. The samples were gently vortexed before 380 μl (technical duplicates for each biological sample) was removed and placed in a 2 ml Eppendorf with 20 μl AA (22.5 mmol/L in water; final concentration of 1 mmol/L and...
50 µL EC (4 µg/ml in water). The samples were vortexed for 10 s and subsequently 1 ml of hexane (Sigma Aldrich, Dorset, United Kingdom) was added drop-wise to the Eppendorf tube. The samples were vortexed for 1 min and centrifuged at 17,000g (4°C) for 10 min. The top fat layer was removed to waste and the sample was placed back on ice; 500 µl of ice-cold ethyl acetate was added and the procedure continued as for urine. The only changes in relation to the urine protocol were the addition of 1.5 ml acetonitrile to the sample remaining after the ethyl acetate extraction (therefore the preweighed tube was a 2-ml Eppendorf) and the injection of 10 µl for LC-MS/MS analysis. Prepared samples were stored at −20°C and defrosted on ice before LC-MS/MS analysis.

2.6.3. Blister fluid analysis
Blister samples were removed from −80°C storage and thawed on ice. The initial volumes were recorded (101±4 µl). The whole procedure was performed on ice and immediately analyzed by LC-MS/MS. Two technical replicates were performed for each biological sample when there was -80 µl initially. The samples were gently vortexed and briefly spun down. Blister fluid (40 µl) was added to an Eppendorf, along with 10 µl of 0.4 mol/L NaH2PO4 solution (containing 200 g/L AA, 1 g/L EDTA and 0.04 µg/10 µl EG). Ice-cold ethyl acetate (300 µl) was added and the sample followed the same procedure as for urine; however, 160 µl acetonitrile was used, the sample was only centrifuged at 17,000g (4°C) for 5 min and the samples were reconstituted back to 20 µl using water before vortexing for 1 min after reweighing the Eppendorf tubes. Of the sample, 18 µl was collected and added to the corresponding dried-down ethyl acetate tube with 2 µl taxifolin (20 µg/ml in 50% acetonitrile and 1% AA). The samples were sonicated for 5 min and 9.5 µl was added to two wells on a covered microwell plate and 5 µl of the sample was injected for LC-MS/MS analysis.

2.6.4. Biopsy analysis
Skin biopsies were removed from −80°C storage and the initial weights were recorded using preweighed 2-ml Eppendorf tubes. The procedure was conducted on ice prior to immediate analysis by LC-MS/MS. The biopsies were held with sterilized tweezers over a waste beaker and flushed with ice-cold hexane to remove any blood and lipid present on the outer layer. After washing with hexane, a stainless-steel rod and base were placed into a vat of liquid nitrogen for approximately 1 min until effervescing ceased. This was removed and, using tweezers, a biopsy was placed into the vat of liquid nitrogen until effervescing stopped. The biopsy was removed, placed in between the rod and base and pulverized with a hammer (cryopulverization). The sample was immediately placed back into the 2-ml Eppendorf tube using a scalpel and tweezers and was stored at −80°C until required. In between each biopsy procedure, the scalpel and tweezers were resterilized using 70% ethanol and hot water.

Prior to LC-MS/MS analysis, each pulverized sample was further homogenized using a microhomogenizer (Ultra Turrax, IKA T10 Basic; IKA Ltd, Cheshire, United Kingdom). To the 2-ml Eppendorf tube containing the cryopulverized biopsy sample, 100 µl ice-cold chloroform (with 0.1 g/l butylated hydroxytoluene; Fisher Scientific Ltd, Leicestershire, United Kingdom) and 100 µl ice-cold sodium dithionite (0.3 mol/L, with 0.08 µg EG; Sigma Aldrich, Dorset, United Kingdom) were added. The biopsy was homogenized by shearing of the samples on dry ice, to reduce the heat produced by the shearing process. After homogenization (for approximately 5 min), the sample was maintained on dry ice for 2 min before centrifuging for 2 min at 17,000g (4°C). The top aqueous layer was removed to a new Eppendorf tube and 100 µl of 0.3 mol/L sodium dithionite (not containing EG) was added to the biopsy sample, which was then vortexed for 1 min. The sample was placed on dry ice for 2 min and centrifuged again with the resulting top aqueous layer being combined with the previous.

Ice-cold ethyl acetate (500 µl) was added and the sample followed the same procedure as for urine; however, 600 µl acetonitrile was used. The samples were reconstituted at 40 µl with water and 36 µl was added to the corresponding dried-down ethyl acetate Eppendorf, alongside 4 µl taxifolin (20 µg/ml in 50% acetonitrile and 1% AA). The samples were sonicated for 5 min and 18 µl was added to two separate wells on a covered microwell plate prior to LC-MS/MS analysis (injection volume: 10 µl).

2.6.5. LC-MS/MS analysis
Reverse-phase LC-MS/MS was performed as previously described [32], using an Agilent 1200 SL system (Agilent Technologies, Dorset, United Kingdom) connected to a 6410 triple quadrupole LC-MS/MS with electrospray ionization on the negative mode, with multiple reaction monitoring (Agilent Technologies, Santa Clara, CA, USA) with a Kinex C18 column (2.6 µm, 150×2.1 mm; Phenomenex, Cheshire, United Kingdom). As green tea catechin conjugates (sulfate and glucuronide) are not commercially available, catechin conjugates were analyzed using peak area, and free forms were presented and will therefore be referred to as O-methyl-catechin-O-sulfate and O-methyl-catechin-O-glucuronide. As green tea catechin metabolites were detected after 1 h, except for EC-O-glucuronide, which was first detected 1.5 h postsupplementation. T_{max} values were calculated for the individual metabolites and ranged between 3 and 4 h. T_{max} values were calculated as peak area relative to the internal standard and ranged between 0.03 and 0.2. The pharmacokinetics for the 11 subjects were collated and presented as the mean±SE and also as individual pharmacokinetic curves. Example pharmacokinetics for O-methyl-EC-EC-O-sulfate, EC-O-sulfate and EG-O-glucuronide are displayed in Fig. 1.

There were 26 green tea catechin metabolites present in the plasma samples after 3 months supplementation, obtained 3 h postconsumption of the final dose of the supplement (Table 4). In comparison to the 3-h postconsumption sample on day 0 of supplementation, there were 7 additional metabolites present in the 3-month samples, including the gut microbiota metabolites, valerolactones (M4-O-sulfate, M4-O-glucuronide and M6/M6′-O-glucuronide) and a significant increase in EC-O-sulfate and M6/M6′-O-sulfate.

### Table 2

| Compound                          | Plasma         | Blister fluid | Skin biopsy |
|-----------------------------------|----------------|---------------|-------------|
| EC                                | 107±14         | 90±2          | 102±27      |
| EGC                               | 103±3          | 75±8          | 105±6       |
| EC-O-sulfate                      | 117±2          | 86±2          | 108±15      |
| EG-O-glucuronide                  | 97±2           | 32±5          | 62±13       |
| EG                                | 93±1           | 104±13        | 96±4        |

Recovery data are expressed as percentages of corresponding standards (mean±SE). Recoveries were performed in technical triplicate at a minimum of three concentrations. EC, epicatechin; EG, ethyl gallate; EGC, epigallocatechin.

### 3. Results

#### 3.1. Subjects

One subject was excluded from analysis as the subject could not provide blood samples. Thus, 11 subjects (six males, five females; median age, 21 years; range, 18–58 years) completed the study and no side effects were reported. BMI was median (range) 24.4 (18.2–33.8) at baseline, 24.9 (18.2–34.5) at 6 weeks and 24.3 (17.8–34.8) at 12 weeks, with no significant change.

#### 3.2. Recovery of the metabolites and conjugates from skin and plasma samples

EC, EGC, EC-O-sulfate and EG-O-glucuronide recoveries and the limit of quantification (LOQ) for the different sample types are shown in Tables 2 and 3. The coefficient of variance for the recovery of spiked catechins and conjugates from plasma, blister and skin biopsy samples ranged from 0.01 to 0.1, 0.03 to 0.2 and 0.1, respectively, indicating that sample processing resulted in suitable reproducibility.

The majority of the standards were recovered between 90% and 100% in the biological samples, except for EG-O-glucuronide in the blister and biopsy samples. The exact chemical substitution positions of the conjugate moieties (methyl ester, sulfate ester and glucuronic acid) of the green tea catechin metabolites are unknown in the results presented and will therefore be referred to as O-methyl-catechin-O-glucuronide or O-methyl-catechin-O-sulfate.

### 3.3. Plasma pharmacokinetics

The green tea catechin metabolites were detected after 1 h, except for EC-O-glucuronide, which was first detected 1.5 h postsupplementation. T_{max} values were calculated for the individual metabolites and ranged between 3 and 4 h. T_{max} values were calculated as peak area relative to the internal standard and ranged between 0.03 and 0.2. The pharmacokinetics for the 11 subjects were collated and presented as the mean±SE and also as individual pharmacokinetic curves. Example pharmacokinetics for O-methyl-EC-EC-O-sulfate, EC-O-sulfate and EG-O-glucuronide are displayed in Fig. 1.

There were 26 green tea catechin metabolites present in the plasma samples after 3 months supplementation, obtained 3 h postconsumption of the final dose of the supplement (Table 4). In comparison to the 3-h postconsumption sample on day 0 of supplementation, there were 7 additional metabolites present in the 3-month samples, including the gut microbiota metabolites, valerolactones (M4-O-sulfate, M4-O-glucuronide and M6/M6′-O-glucuronide) and a significant increase in EC-O-sulfate and M6/M6′-O-sulfate.
3.4. Blister fluid

We identified 20 green tea catechin metabolites in blister fluid, with few detected in baseline samples and the majority identified post green tea supplementation for 3 months (Table 5). The most prominent conjugated forms of EC and EGC, identified as the largest peak areas relative to the internal standard, were EC-O-sulfate, O-methyl-EC-O-sulfate and O-methyl-EGC-O-sulfate. For the valerolactones, M6/M6′-O-sulfate and O-methyl-M4-O-sulfate had the highest corresponding peak areas relative to the internal standard. O-Methyl-M4-O-sulfate was the only metabolite that was significantly increased in the postsupplementation UVR sample compared to the no-UVR sample.

3.5. Skin biopsy

Metabolites identified in the skin biopsy samples postsupplementation were O-methyl-EC-O-sulfate, gallic acid-O-glucuronide, O-methyl-gallic acid-O-sulfate, O-methyl-gallic acid-O-glucuronide, quercetin and M6 (Table 6). M6 was present in each sample from one volunteer and was the only metabolite identified in the presupplementation samples. No significant difference was found between the green tea catechin conjugates and metabolites present in the pre-UVR and post-UVR skin biopsies.

Table 3
LOQ for the free-form green tea catechin metabolites (related to sulfate or glucuronide forms) for each biological sample.

| Compound                  | LOQ Plasma pmol/L | LOQ Blister fluid pmol/L | LOQ Skin tissue biopsy pmol/mg tissue |
|---------------------------|-------------------|--------------------------|-------------------------------------|
| EC                        | 2                 | 20                       | NA                                  |
| 3′-O-Me EC                | 1                 | 20                       | NA                                  |
| 4′-O-Me EC                | 0.1               | 20                       | NA                                  |
| EGC                       | 0.2               | 10                       | NA                                  |
| 3′-O-Me EGC               | 1                 | 1                        | NA                                  |
| 4′-O-Me EGC               | 0.6               | 230                      | NA                                  |
| ECG                       | 0.1               | NA                       | NA                                  |
| EGC                       | 0.1               | NA                       | NA                                  |
| Gallic acid               | 40                | 110                      | NA                                  |
| 3-O-Me gallic acid        | 2                 | 10                       | 10                                  |
| Quercetin                 | 20                | 60                       | 30                                  |
| Kaempferol                | 110               | NA                       | NA                                  |
| M6                        | 3                 | 30                       | 9                                   |
| Syringic acid             | 20                | 40                       | NA                                  |
| 3-Hydroxybenzoic acid     | 5                 | 30                       | NA                                  |
| Benzoic acid              | 50                | 590                      | NA                                  |
| Hippuric acid             | 0.4               | 40                       | NA                                  |

EC, epicatechin; ECG, epicatechin gallate; EGC, epigallocatechin gallate; Me, methyl; NA, not assessed using free-form standards, as the free-form or associated sulfate or glucuronide form was not identified in a sample.
Data for the conjugated forms are the average peak area ratio (×10 geometrical mean). Not detected (ND).

| Compound                        | Ingestion of green tea supplement |
|---------------------------------|----------------------------------|
|                                 | 3 h, day 0                       | 3 h, 3 months                   |
| Conjugated form                 | Peak area ratio                  | Peak area ratio                 |
| EC-O-sulfate                    | 14±2 (10)                        | 23±4 (11)                       |
| EC-O-glucuronide                | 4±1 (7)                          | 5±1 (7)                         |
| O-Me-EC-O-sulfate               | 13±2 (10)                        | 21±4 (11)                       |
| EGC-O-sulfate                   | 4±1 (3)                          | 3±3 (0.7)                       |
| EGC-O-glucuronide               | 5±2 (7)                          | 8±2 (10)                        |
| O-Me-EGC-O-sulfate              | 10±2 (9)                         | 12±2 (11)                       |
| O-Me-EGC-O-glucuronide          | 1.8±0.5 (3)                      | 1.9±0.4 (6)                     |
| EGC-O-sulfate                   | ND                               | 3 (1)                           |
| Gallic acid-O-sulfate           | ND                               | 4±1 (2)                         |
| O-Me-gallic acid-O-sulfate      | 40±7 (11)                        | 50±9 (11)                       |
| Quercetin-O-sulfate             | ND                               | 2±5 (0.4)                       |
| Kaempferol-O-glucuronide        | ND                               | 3 (1)                           |
| M4-O-sulfate                    | ND                               | 10±2 (9)                        |
| M4-O-glucuronide                | ND                               | 2±0.7 (5)                       |
| O-Me-M4-O-sulfate               | 1 (1)                            | 3±8 (8)                         |
| M6/M6′-O-sulfate                | 10±4 (8)                         | 6±20 (11)                       |
| M6/M6′-O-glucuronide            | ND                               | 5±2 (7)                         |
| O-Me-M6/M6′-O-sulfate           | 4±2 (3)                          | 5.6±0.4 (2)                     |
| Benzoic acid-O-sulfate          | 19±6 (11)                        | 14±3 (10)                       |
| 3-Hydroxybenzoic acid-O-sulfate | 1 (1)                            | 6±3 (3)                         |
| Syringic acid-O-sulfate         | 7±6 (4)                          | 3±1 (5)                         |
| Free form                       | μM                              | μM                              |
| EGC                              | 0.2 (1)                          | 0.24±0.01 (2)                   |
| EGC                              | 0.08 (1)                         | 0.25±0.04 (2)                   |
| EGC                              | 0.10±0.02 (4)                    | 0.3±0.1 (4)                     |
| 3-Hydroxybenzoic acid           | 4±1 (5)                          | 9±3 (7)                         |
| Hippuric acid                   | 1.4±0.4 (10)                     | 1.6±0.2 (11)                    |

Data for the conjugated forms are the average peak area ratio (×10 geometrical mean) of the compound relative to the internal standard, EC (2 μg/ml). Data are presented as mean±SE, and the data in brackets are the number of subjects in which the metabolite was identified. When no SE is presented, the metabolite was only detected in one volunteer. Samples were analyzed in biological duplicate and technical triplicate. EC, epicatechin; EGC, epicatechin gallate; EGC, epigallocatechin; EGC, epigallocatechin gallate; Me, methyl; ND, not detected.

3.6. Bioavailability of green tea catechin metabolites

There were 15 green tea catechin metabolites (both free and conjugated forms) present in at least two of the biological samples, which were EC-O-sulfate, O-methyl-EC-O-sulfate, EGC-O-glucuronide, O-methyl-EGC-O-sulfate, EC, epicatechin; EGC, epicatechin gallate; EGC, epigallocatechin; EGC, epigallocatechin gallate; Me, methyl; ND, not detected.

Table 6: Green tea catechin metabolites in skin biopsies presupplementation and postsupplementation, with or without UVR exposure.

| Compound                        | Amount/biopsy weight |
|---------------------------------|----------------------|
|                                 | Pre, No UVR          | Pre, UVR              | Post, No UVR          | Post, UVR              |
| Conjugated form                 | Peak area ratio/mg   | Peak area ratio/mg   | Peak area ratio/mg   | Peak area ratio/mg   |
| O-Me-EC-O-sulfate               | ND                   | ND                   | 5±3 (10)             | 5±3 (8)               |
| Gallic acid-O-glucuronide       | ND                   | ND                   | 4±2 (8)              | 4±3 (10)             |
| O-Me-gallic acid-O-sulfate      | ND                   | ND                   | 2±2 (2)              | 3±3 (2)              |
| O-Me-EC-O-glucuronide           | ND                   | ND                   | 3±2 (6)              | 2±7 (7)              |
| O-Me-EGC-O-glucuronide          | ND                   | ND                   | 1 (1)                | 2 (1)                |
| Gallic acid-O-glucuronide       | ND                   | ND                   | 0.7±0.4 (2)          | 4 (1)                |
| O-Me-M4-O-sulfate               | ND                   | ND                   | 9±6 (6)              | 14±8° (7)            |
| M6/M6′-O-sulfate                | 7±4 (3)              | 15±4 (16)            | 46±47 (10)           | 78±88 (9)            |
| Benzoic acid-O-sulfate          | ND                   | ND                   | 3±3 (4)              | 6±5 (4)              |
| Syringic acid-O-sulfate         | ND                   | ND                   | 2 (1)                | 4±3 (4)              |
| Syringic acid-O-glucuronide     | ND                   | ND                   | 2 (1)                | ND                   |
| 3-Hydroxybenzoic acid-O-sulfate | ND                   | ND                   | 8 (1)                | 8±6 (3)              |
| Free form                       | pmol/mg              | pmol/mg              | pmol/mg              | pmol/mg              |
| EGC                              | 20 (1)               | 14 (1)               | 9 (1)                | ND                   |
| Hippuric acid                   | 340±380 (11)         | 670±800 (11)         | 230±150 (11)         | 350±330 (11)         |
| Benzoic acid                    | 10,550 (1)           | 30,570 (1)           | ND                   | ND                   |

Data are the average peak area ratio relative to internal standard (EC; 2 μg/ml) ×10 geometrical mean, standardized to the initial weight of the biopsy. Samples were analyzed presupplementation and postsupplementation and with or without UVR irradiation. Samples were analyzed in technical duplicate; mean±SE; data in brackets are the number of subjects in which the metabolite was identified. EC, epicatechin; EG, ethyl gallate; Me, methyl; ND, not detected.

Table 5: Green tea catechin metabolites in blister fluid presupplementation and postsupplementation, with or without UVR exposure.

| Compound                        | Amount/blister fluid collected |
|---------------------------------|--------------------------------|
|                                 | Pre, No UVR          | Pre, UVR              | Post, No UVR          | Post, UVR              |
| Conjugated form                 | Peak area ratio/μl   | Peak area ratio/μl   | Peak area ratio/μl   | Peak area ratio/μl   |
| EC-O-sulfate                    | ND                   | ND                   | 5±3 (10)             | 9±3 (8)               |
| EC-O-glucuronide                | ND                   | ND                   | 4±2 (8)              | 4±3 (10)             |
| O-Me-EC-O-sulfate               | ND                   | ND                   | 2±2 (2)              | 3±3 (2)              |
| EGC-O-sulfate                   | ND                   | ND                   | 3±2 (6)              | 2±7 (7)              |
| O-Me-EGC-O-sulfate              | ND                   | ND                   | 1 (1)                | 2 (1)                |
| Gallic acid-O-glucuronide       | ND                   | ND                   | 0.7±0.4 (2)          | 4 (1)                |
| O-Me-M4-O-sulfate               | ND                   | ND                   | 9±6 (6)              | 14±8° (7)            |
| M6/M6′-O-sulfate                | 7±4 (3)              | 15±4 (16)            | 46±47 (10)           | 78±88 (9)            |
| Benzoic acid-O-sulfate          | ND                   | ND                   | 3±3 (4)              | 6±5 (4)              |
| Syringic acid-O-sulfate         | ND                   | ND                   | 2 (1)                | 4±3 (4)              |
| Syringic acid-O-glucuronide     | ND                   | ND                   | 2 (1)                | ND                   |
| 3-Hydroxybenzoic acid-O-sulfate | ND                   | ND                   | 8 (1)                | 8±6 (3)              |
| Free form                       | pmol/μl             | pmol/μl             | pmol/μl             | pmol/μl             |
| EGC                              | 20 (1)               | 14 (1)               | 9 (1)                | ND                   |
| Hippuric acid                   | 340±380 (11)         | 670±800 (11)         | 230±150 (11)         | 350±330 (11)         |
| Benzoic acid                    | 10,550 (1)           | 30,570 (1)           | ND                   | ND                   |

Data are the average peak area ratio relative to internal standard (EC; 2 μg/ml) ×10 geometrical mean, in total blister fluid extracted for the conjugated forms. Samples were analyzed pre and post 12 weeks supplementation and with or without UVR irradiation. Samples were analyzed in biological duplicate and technical duplicate; mean±SE. The data in brackets are the number of subjects in which the metabolite was identified. EC, epicatechin; EGC, epigallocatechin; EG, ethyl gallate; EGGC, epigallocatechin gallate; ND, not detected.

* P<0.05 compared to post no UVR (two-tailed Wilcoxon signed-rank test).
4. Discussion

The aim of the study was to determine whether green tea catechins and metabolites could be identified in human skin samples (blister fluid and biopsies), whether the bioavailability in skin could be related to their presence in plasma and whether the amounts were affected by UVR exposure. In total, there were 15 metabolites identified after 3 months supplementation in at least two of the three samples (plasma, blister fluid and biopsies) obtained 3 h post green tea supplement consumption, with only O-methyl-gallic acid-O-sulfate and M6/M6′-O-sulfate identified in all three samples. In accordance with other green tea bioavailability studies, there was a large interindividual variation [36,37].

The blister fluid is a vacuum-pressure-induced collection of the extracellular fluid surrounding cells and may contain a contribution from plasma. As expected, the majority of the metabolites identified in more than one tissue sample were present within blister fluid and plasma, with limited metabolites identified in biopsy samples. It is possible that the metabolites did not enter the skin cells, that the metabolites present within the skin biopsy samples were bound to intracellular proteins or that they were further metabolized. A significant finding of the study was the increase in O-methyl-M4-O-sulfate observed in the postsupplementation UVR blister fluid sample compared to no UVR, and this difference may be an increase in response to the external stress. M4 is a hydroxy-phenyl-valerolactone that derives from microbial metabolism of EGC [38] and, as suggested in our previous study, is a biomarker of green tea consumption [31]. M6 (derived from EC consumption) was identified in all biopsy samples (presupplementation and postsupplementation) for one volunteer; however, this was possibly due to dietary consumption of chocolate, black tea or wine and good dietary sources of EC, on the previous day. As a 24-h dietary recall was not undertaken, the other dietary sources of EC were not recorded.

After 3 months daily consumption, the metabolites quantified in the plasma were in line with other studies [25,27–29]. The C_{max} of EGCG was 45 mmol/L when normalized to a 50 mg dose of EGCG in the green tea supplements, which is also in line with previous studies of plasma (reviewed by Williamson et al. [39]). For the first time, quercetin-O-sulfate, kaempferol-O-glucuronide, syringic acid-O-sulfate, 3-hydroxybenzoic acid-O-sulfate and benzoic acid-O-sulfate were identified in plasma samples post green tea consumption. The identification of quercetin and kaempferol after consumption of green tea has been assessed previously in plasma, but only as aglycones post enzyme deconjugation [40,41].

Our preliminary study [31] identified 8 metabolites in the skin biopsy samples. Contrasting with the current work, the free-form (unconjugated) derivatives of the metabolites present following consumption of green tea supplements were only assessed after enzyme deconjugation, and the tissue examined was limited to the dermal layer of the skin. Only one catechin was identified in a biopsy for the current study, whereas EC, EGC, 4′-O-methyl-EGC and EGCG were tentatively identified in the pilot study. This is possibly due to the accumulation of free-form derivatives following enzyme deconjugation, which may result in a higher LC-MS/MS response in comparison to the lower concentrations of the individual conjugates for one particular catechin. However, the current methodology gives a clearer and more realistic overview of both the free-form and conjugated derivatives of the green tea catechin metabolites identified, even though some of the individual metabolites may consequently be under the limit of detection.

This is the first bioavailability study to identify the presence of both free and conjugated forms of green tea catechins and metabolites in skin tissue, blister fluid and plasma. The method reported good recoveries for the majority of the compounds assessed. The main limitation of the study is the lack of commercially available green tea catechin and metabolite conjugated standards, and therefore, the results obtained are speculative. Other analytical methods, such as NMR, could be used to improve the identification of the metabolites within the samples. Overestimation may occur as the conjugated forms ionize more efficiently and the precise response factors are also unknown; therefore, the green tea catechins were reported relative to standards and the conjugated forms were reported as peak areas relative to the internal standard to improve the quality of the data.

In summary, the results of the study suggest that green tea catechin metabolites can reach the skin postsupplementation in the unconjugated (free) form and as conjugated derivatives, as assessed using a dual combination method to identify both [32], with an increase in O-methyl-M4-O-sulfate following UVR exposure in blister fluid. As expected, the majority of metabolites were present in the conjugated form. There was a clear overlap between the metabolites present in the plasma samples collected 3 h postconsumption and the blister fluid. Therefore, any lowering of UVR-induced inflammatory markers or improvement to skin health reported in future studies following long-term green tea supplementation could potentially be associated with the metabolites reported in the present study.

Acknowledgments

The authors would like to thank Miss Susan Bennett for the assistance in sample collection and Dr Joanne Maycock for assisting with the biopsy sample preparation. Thank you to Dr Begeña Bartolomé (Consejo Superior de Investigaciones Científicas, Spain) for the kind gift of the valerolactone. The present work was supported by the Biotechnology and Biological Sciences Research Council, Diet and Health Research Industry Club, United Kingdom (grants BB/G005559/1 and BB/G30125/1).

References

[1] Lambert JD, Sang S, Yang CS. Biotransformation of green tea polyphenols and the biological activities of those metabolites. Mol Pharm 2007;4:819–25.
[2] Wu CH, Yeh CT, Yeh GC. Epigallocatechin gallate (EGCG) binds to low-density lipoproteins (LDL) and protects them from oxidation and glycation under high-glucose conditions mimicking diabetes. Food Chem 2010;121:639–44.
[3] Bogdanski P, Suliburska J, Szułniska M, Stepien M, Pupek-Musialik D, Jabłeczek A. Green tea extract reduces blood pressure, inflammatory biomarkers, and oxidative stress and improves parameters associated with insulin resistance in obese, hypertensive patients. Nutr Res 2012;32:421–7.
[4] Yuan JM. Cancer prevention by green tea: evidence from epidemiologic studies. Am J Clin Nutr 2013;98:1676S–81S.
[5] Singh T, Katkay SK. Green tea polyphenol, (→)epigallocatechin-3-gallate, induces toxicity in human skin cancer cells by targeting beta-catenin signaling. Toxicol Appl Pharmacol 2013;273:418–24.
[6] Lambert JD. Does tea prevent cancer? Evidence from laboratory and human intervention studies. Am J Clin Nutr 2013;98:1667S–75S.
Fung ST, Flowers N, Holmes J, Clarke A, Stranges S, Hooper L, et al. Green and black tea for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013;6:CD009934.

Afaq F, Syed DN, Malik A, Hadi N, Sarfaraz S, Kweon MH, et al. Delphinidin, an anthocyanin in pigmented fruits and vegetables, protects human HaCaT keratinocytes and mouse skin against UVB-mediated oxidative stress and apoptosis. J Invest Dermatol 2007;127:222–32.

Hwang YP, Oh KN, Yun HJ, Jeong HG. The flavonoids apigenin and luteolin suppress ultraviolet A-induced matrix metalloproteinase-1 expression via MAPKs and AP-1-dependent signaling in HaCaT cells. J Dermatol Sci 2011;61:23–31.

Poquet L, Clifford MN, Williamson G. Effect of dihydrocaffeic acid on UV irradiation of human keratinocyte HaCaT cells. Arch Biochem Biophys 2008;476:196–204.

Heinrich U, Moore CE, De Spirt S, Trommer H, Stahl W. Green tea polyphenols provide photoprotection, increase microcirculation, and modulate skin properties of women. J Nutr 2011;141:1202–8.

Afaq F, Adhami VM, Ahmad N, Mukhtar H. Inhibition of ultraviolet B-mediated activation of nuclear factor kappa B in normal human epidermal keratinocytes by green tea constituent (−)-epigallocatechin-3-gallate. Oncogene 2003;22:1035–44.

Song XZ, Bi ZG, Xu AE. Green tea polyphenol epigallocatechin-3-gallate inhibits the expression of nitric oxide synthase and generation of nitric oxide induced by ultraviolet B in HaCaT cells. Chin Med J (Engl) 2006;119:282–7.

Wu LY, Zheng XQ, Lu JL, Liang YR. Protective effect of green tea polyphenols against ultraviolet B-induced damage to HaCaT cells. Hum Cell 2009;22:18–24.

Haaake A, Scott GA, Hollbrook KA. Structure and function of the skin: overview of the epidermis and dermis. In: Freinkel RK, Woodley DT, editors. The biology of the skin. 1st edit. New York: Parthenon; 2001. p. 19–46.

Sies H, Stahl W. Carotenoids and UV protection. Photochem Photobiol Sci 2004;3:749–52.

Trautinger F. Mechanisms of photodamage of the skin and its functional consequences for skin ageing. Clin Exp Dermatol 2001;26:573–7.

Rhodes LE, Credhill K, Masoodi M, Haylett AK, Brownrigg M, Thody AJ, et al. The sunburn response in human skin is characterized by sequential eicosanoid production and activation of nuclear factor kappa B in normal human epidermal keratinocytes by green tea constituent (−)-epigallocatechin-3-gallate. Oncogene 2003;22:1035–44.

McArdle F, Rhodes LE, Parslew R, Jack CIA, Friedmann PS, Jackson MJ. UVR-induced oxidative stress in human skin in vivo: effects of oral vitamin C supplementation. Free Radic Biol Med 2002;33:1355–62.

Mullen W, Borges G, Lean ME, Roberts SA, Crozier A. Identification of metabolites that may mediate its early and late phases. FASEB J 2009;23:3947–56.

Hollman PC, Van Het Hof KH, Tijburg LB, Katan MB. Addition of milk does not affect the fate of (−)-4-H-3 epigallocatechin gallate in rats after oral administration. J Agric Food Chem 2001;49:4102–12.

Rhodes LE, Darby G, Massey KA, Clarke KA, Dew TP, Farrar MD, et al. Oral green tea catechin metabolites are incorporated into human skin and protect against UV radiation-induced cutaneous inflammation in association with reduced production of pro-inflammatory eicosanoids 12-hydroxyeicosatetraenoic acid. Br J Nutr 2013;110:891–900.

Cancer Research UK. Skin cancer incidence statistics. Version current 22 April 2014. Internet: http://www.cancerresearchuk.org/cancer-info/cancerstats/types/skin/incidence. [accessed 1 October 2014].

Del Rio D, Calani L, Cordero C, Salvatore S, Pellegrini N, Brighenti F. Bioavailability and catabolism of green tea flavan-3-ols in humans. Nutrition 2010;26:1110–6.

Stalmach A, Troufflard S, Serafini M, Crozier A. Absorption, metabolism and excretion of Choladi green tea flavan-3-ols by humans. Mol Nutr Food Res 2009;53:544–53.

Del Rio D, Calani L, Scanzina F, Jechiu L, Cordero C, Brighenti F. Bioavailability of catechins from ready-to-drink tea. Nutrition 2010;26:528–33.

Mullen W, Rogers G, Lean ME, Roberts SA, Crozier A. Identification of metabolites in human plasma and urine after consumption of a polyphenol-rich juice drink. J Agric Food Chem 2010;58:2586–95.

Wang PW, Aronson WJ, Huang M, Zhang YJ, Lee RP, Heber D, et al. Green tea polyphenols and metabolites in prostatic tissue: implications for cancer prevention. Cancer Prev Res (Phila) 2010;3:985–93.

Kohri T, Matsumoto N, Yamakawa M, Suzuki M, Nonjo F, Hara Y, et al. Metabolic fate of (−)-4-H-3 epigallocatechin gallate in rats after oral administration. J Agric Food Chem 2001;49:4102–12.

Pfeifer GP, You YH, Besaratinia A. Mutations induced by ultraviolet light. Mutat Res 1987;210:297–304.